Karuna Therapeutics, Inc (KRTX)

Etorro trading 970x250
Karuna Therapeutics, Inc (KRTX) Logo

About Karuna Therapeutics, Inc

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Address: 33 Arch Street, Boston, MA, United States, 02110

Karuna Therapeutics, Inc News and around…

Latest news about Karuna Therapeutics, Inc (KRTX) common stock and company :

Sum Up The Parts: FPX Could Be Worth $144
19 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $144.09 per unit.

Karuna Therapeutics Earns Technical Rating Upgrade
14 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Karuna Therapeutics shows improving technical performance. Will it continue?

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

IBD Rating Upgrades: Karuna Therapeutics Shows Improved Relative Price Strength
24 Sep, 2021 FinancialContent

Karuna Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

KRTX Makes Notable Cross Below Critical Moving Average
16 Sep, 2021 FinancialContent

In trading on Thursday, shares of Karuna Therapeutics Inc (KRTX) crossed below their 200 day moving average of $113.34, changing hands as low as $113.06 per share. Karuna Therapeutics Inc shares are currently trading up about 0.1% on the day..

Stocks With Rising Relative Price Strength: Karuna Therapeutics
03 Sep, 2021 FinancialContent

Karuna Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 82.

Karuna Therapeutics to Present at 2021 Virtual Wells Fargo Healthcare Conference
01 Sep, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in a fireside chat at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 8:40 a.m. ET.

Stocks With Rising Relative Strength: Karuna Therapeutics
01 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for Karuna Therapeutics shows improving technical performance. Will it continue?

Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference
31 Aug, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will participate in a panel titled “Emerging Therapies for Psychiatric Disorders” at the Citi 16th Annual BioPharma Virtual Conference on September 8, 2021, at 10:40 a.m. ET.

PureTech Health plc – Half-Year Report
24 Aug, 2021 FinancialContent

PureTech Health (Nasdaq: PRTC, LSE: PRTC) today announces its half-yearly results for the six months ended June 30, 2021.

Karuna Therapeutics Reports Second Quarter 2021 Financial Results and Provides General Business Update
05 Aug, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2021 and provided a general business update.

Karuna Therapeutics to Present at 2021 Wedbush PacGrow Healthcare Virtual Conference
03 Aug, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman will participate in a panel titled “The Brains of the Operation - Novel Approaches in Neuro” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021 at 12:00 p.m. ET.

Stock Upgrades: Karuna Therapeutics Shows Rising Relative Strength
29 Jul, 2021 FinancialContent

A Relative Strength Rating upgrade for Karuna Therapeutics shows improving technical performance. Will it continue?

Peek Under The Hood: FPX Has 10% Upside
28 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $138.29 per unit.

Notable Two Hundred Day Moving Average Cross - KRTX
27 Jul, 2021 FinancialContent

In trading on Tuesday, shares of Karuna Therapeutics Inc (KRTX) crossed below their 200 day moving average of $109.04, changing hands as low as $106.99 per share. Karuna Therapeutics Inc shares are currently trading down about 2.7% on the day..

Snag This Bargain Even Cheaper Than Director Healy Did
26 Jul, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on July 2, Karuna Therapeutics Inc's Director, James Healy, invested $74,923.09 into 636 shares of KRTX, for a cost per share of $117.80..

IBD Rating Upgrades: Karuna Therapeutics Flashes Improved Price Strength
20 Jul, 2021 FinancialContent

Karuna Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Hedge Funds Are Crazy About Karuna Therapeutics, Inc. (KRTX)
20 Jul, 2021 Yahoo! Finance

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

Karuna Therapeutics Gets RS Rating Upgrade
13 Jul, 2021 FinancialContent

A Relative Strength Rating upgrade for Karuna Therapeutics shows improving technical performance. Will it continue?

The 20 best-performing IPOs of the past three years have returned up to 1,477%
24 Jun, 2021 FinancialContent

These stock-market winners include BioNTech, Zoom, CrowdStrike and Nio.

PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
23 Jun, 2021 FinancialContent

PureTech Founded Entity Karuna Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
23 Jun, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers. The Company had previously announced a preliminary analysis of data from the first two cohorts in the trial earlier this year. Based on results from the Phase 1b trial in healthy elderly volunteers, the Company plans to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022.

Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
23 Jun, 2021 Yahoo! Finance

BOSTON, June 23, 2021--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers. The Company had previously announced a preliminary analysis of data from the first two cohorts in the trial earlier th

The Math Shows FPX Can Go To $137
16 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $136.86 per unit.

Biotechs Ready To Roar
13 Jun, 2021 FinancialContent

The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector for many reasons.

Karuna Therapeutics to Present at Upcoming Investor Conferences
02 Jun, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming virtual investor conferences:

Is It Too Late to Buy Karuna Therapeutics (KRTX) Stock?
26 May, 2021 Yahoo! Finance

Miller Value Partners recently released its Q1 2021 Investor Letter, a copy of which you can download here. The Miller Opportunity Trust posted solid gains, with Class I up 16.67%, outperforming its benchmark, the S&P 500 Index which returned 6.17% in the same quarter. You should check out Miller Value Partners’ top 5 stock picks […]

Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update
06 May, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2021 and provided a general business update.

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Karuna Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
27 Apr, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / April 27, 2021 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Karuna Therapeutics, Inc.If you are a shareholder of Karuna Therapeutics, Inc.

10 Biggest Price Target Changes For Monday
26 Apr, 2021 FinancialContent

Credit Suisse boosted Facebook, Inc. (NASDAQ: FB) price target from $330 to $371. Facebook shares rose 0.4% to $302.18 in pre-market ...

Karuna Therapeutics, Inc (KRTX) is a NASDAQ Common Stock listed in , ,

970x250